Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | KDM6A | O15550 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KDM5C | P41229 | 1/20 | 0.38 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.38 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.38 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | APEX1 | P27695 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1665468 | 0.80 | BRD4 (0.38) | ALDH1A1SMN1; SMN2KDM4EKDM6AKDM4A | |
| SCHEMBL2781478 | 0.77 | NOTUM (0.41) | ALDH1A1SMN1; SMN2KDM4EKDM6AKDM4A | |
| SCHEMBL11286998 | 0.77 | KDM4E (0.46) | ALDH1A1SMN1; SMN2KDM4EMAPTTDP1 | |
| SCHEMBL12494600 | 0.76 | KDM4E (0.33) | ALDH1A1SMN1; SMN2KDM4EKDM6AKDM4A | |
| SCHEMBL27341809 | 0.76 | DPP4 (0.39) | ALDH1A1SMN1; SMN2KDM4EKDM6AKDM4A | |
| SCHEMBL5154367 | 0.76 | KDM4E (0.33) | ALDH1A1KDM4EKDM6AKDM4ACYP2C9 | |
| SCHEMBL28872653 | 0.76 | GPR35 (0.40) | ALDH1A1KDM4EKDM6AKDM4ACYP2C9 | |
| SCHEMBL12494601 | 0.76 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2KDM4ENOTUMMEN1 | |
| SCHEMBL27302249 | 0.74 | KDM4E (0.39) | ALDH1A1SMN1; SMN2KDM4EKDM6AKDM4A | |
| SCHEMBL12821451 | 0.74 | LMNA (0.32) | ALDH1A1TDP1HSD17B10ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4578451-A2 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | Novartis AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| US-20250179061-A1 | RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2025-06-05 | — | — | US | disclosed |
| EP-4214210-B1 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | NOVARTIS AG (CH) | 2025-04-09 | — | — | EP | disclosed |
| EP-3879617-B1 | ELECTROLYTE FOR LITHIUM SECONDARY BATTERY, AND LITHIUM SECONDARY BATTERY INCLUDING THE SAME | LG ENERGY SOLUTION LTD (KR) | 2025-04-02 | — | — | EP | disclosed |
| CN-119365460-A | Compounds that interact with Ras superfamily proteins for the treatment of cancer, inflammatory diseases, RAS diseases, and fibrotic diseases | 尚医治疗有限责任公司 | 2025-01-24 | — | — | CN | disclosed |
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | NOVARTIS AG (CH) | 2023-11-16 | — | — | US | disclosed |
| CN-116063326-A | Amino-containing macrocyclic compounds as protein kinase modulators | 赛诺哈勃药业（成都）有限公司 | 2023-05-05 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2009133348-A1 | AMINOPYRIDINE DERIVATIVES | VANTIA LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
| EP-1372651-B1 | NOVEL AMIDES, PREPARATION AND THERAPEUTIC USE AS MODULATORS OF CCR-RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2007-03-07 | — | — | EP | disclosed |
| CN-1538844-A | Novel amides as modulators of CCR receptor activity, their preparation and therapeutic use | — | 2004-10-20 | — | — | CN | disclosed |
| EP-1372651-A1 | NOVEL AMIDES, PREPARATION AND THERAPEUTIC USE AS MODULATORS OF CCR-RECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002076457-A1 | NOVEL AMIDES, PREPARATION AND THERAPEUTIC USE AS MODULATORS OF CCR-RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2002-10-03 | — | — | WO | disclosed |
| CN-1058490-C | Tetrazolinone derivatives | BAYER AGROCHEM KK (JP) | 2000-11-15 | — | — | CN | disclosed |
| EP-0695748-B1 | Tetrazolinone herbicides | BAYER AGROCHEM KK (JP) | 1999-05-06 | — | — | EP | disclosed |
| US-5589439-A | HERBICIDES | NIHON BAYER AGROCHEM K.K. (JP) | 1996-12-31 | — | — | US | disclosed |
| EP-0695748-A1 | Tetrazolinone herbicides | NIHON BAYER AGROCHEM K.K. (JP) | 1996-02-07 | — | — | EP | disclosed |
| US-4194003-A | New pyrrole derivatives, process for their preparation and therapeutic applications thereof | ALBERT ROLLAND S.A. (FR) | 1980-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365571-A1 | COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS | SPPL2A, SPPL2B, BACE1 | ALDH1A1 3565/4885SMN1; SMN2 2626/4885KDM4E 4701/4885 |
| US-20250179061-A1 | RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF | RIPK1, RIPK2, RIPK3 | ALDH1A1 4611/4885SMN1; SMN2 1610/4885KDM4E 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.